FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study

• DOI: 10.3389/fonc.2024.1375906
• Publication Date: 2024-04-04T05:14:30Z
• Authors: Wenwei Yang; Dong Chen; Yaru Niu; Guifu Wu; Zhangkan Huang; Xinyu Bi; Hong Zhao; Xu Che; Yongkun Sun
• Keywords: Regimen; Clinical endpoint; Progression-free survival

Purpose To explore the efficacy and safety of FOLFOXIRI plus cetuximab regimen as conversion therapy for patients with unresectable RAS/BRAF wild-type colorectal liver-limited metastases (CLM). Patients methods This was a dual-center, phase II trial rate no evidence disease (NED) achieved primary endpoint. All enrolled initially left-sided received modified therapy. Results Between October 2019 2021, fifteen were enrolled. Nine (60%) NED. The overall response (ORR) 92.9%, control (DCR) 100%. median relapse‐free survival (RFS) 9 (95% CI: 0–20.7) months. progression-free (PFS) 13.0 months 5.7-20.5), (OS) not reached. most frequently occurring grade 3-4 adverse events neutropenia (20%), peripheral neurotoxicity (13.3%), diarrhea (6.7%), rash acneiform (6.7%). Conclusion displayed tolerable toxicity promising anti-tumor activity in terms NED CLM. merits further investigation.